Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study suggests that CRF receptor 1 antagonism may have specific effects within neural circuitry mediating fear inhibition responses, but not overall symptom presentation, in PTSD.
|
30807663 |
2020 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, analysis of cerebrospinal fluid in patients with PTSD showed no significant changes in corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, or insulin-like growth factor 1.Substance P was found to be decreased.
|
31675389 |
2019 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysfunction of the CRF system has been observed in stress-related affective disorders including post-traumatic stress disorder, depression, and anxiety.
|
31212019 |
2019 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Corticotropin-releasing factor-1 (CRF-1) is one of the most validated targets for the development of antagonists against depression, anxiety and post-traumatic stress disorders.
|
30124114 |
2019 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of oxytocin on prosocial behavior and the associated profiles of oxytocinergic and corticotropin-releasing hormone receptors in a rodent model of posttraumatic stress disorder.
|
30898126 |
2019 |
Post-Traumatic Stress Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Disturbed sleep is a core feature of posttraumatic stress disorder (PTSD), characterized in part by decreased delta power sleep that may result from stress-related alterations in corticotropin releasing factor (CRF), hypothalamic pituitary adrenal axis (HPA) regulation and glucocorticoid signaling.
|
29268182 |
2018 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examine placebo effects across self-reported, clinically rated, and performance-based data from a trial using a corticotropin-releasing hormone receptor type 1 (CRHR1) antagonist for treatment of post-traumatic stress disorder (PTSD).
|
29505471 |
2018 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Substantial preclinical and clinical data indicate abnormalities in the hypothalamic-pituitary-adrenal axis, including signaling by corticotropin-releasing factor, in the pathophysiology of PTSD.
|
28793974 |
2017 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current clinical and pre-clinical data suggest that both cannabinoid agents and blockage of CRF through corticotrophin releasing factor receptor type 1 (CRFr1) may offer therapeutic benefits for post-traumatic stress disorder (PTSD).
|
28663121 |
2017 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of function gene polymorphisms in adrenergic α2-autoreceptors and increased corticotropin-releasing hormone, as observed in PTSD, are also thought to contribute to IBS-D.
|
27898588 |
2017 |
Post-Traumatic Stress Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD.
|
24950747 |
2014 |
Post-Traumatic Stress Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine if single nucleotide polymorphisms of the corticotrophin-releasing hormone binding protein (CRHBP, rs10055255) and CRH receptor type 1 (CRHR1, rs1876831) were associated with posttraumatic stress disorder (PTSD) and depressive symptoms following medical-surgical intensive care unit (ICU) hospitalization.
|
24075295 |
2014 |